References
- MandellLAWunderinkRGPneumoniaFauciABraunwaldEKaserDHarrison’s Internal Medicine18th edNew YorkMac Graw Hill201121302141
- MandellLAWunderinkRGAnzuetoAInfectious Diseases Society of America; American Thoracic SocietyInfectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adultsClin Infect Dis200744Suppl 2S27S7217278083
- GilbertDNProcalcitonin as a biomarker in respiratory tract infectionClin Infect Dis201152Suppl 4S346S35021460294
- BoussekeyNLeroyOAlfandariSDevosPGeorgesHGueryBProcalcitonin kinetics in the prognosis of severe community-acquired pneumoniaIntensive Care Med200632346947216477418
- MasiaMGutierrezFShumCUsefulness of procalcitonin levels in community-acquired pneumonia according to the patients outcome research team pneumonia severity indexChest200512842223222916236878
- Christ-CrainMOpalSMClinical review: the role of biomarkers in the diagnosis and management of community-acquired pneumoniaCrit Care201014120320236471
- MüllerFChrist-CrainMBregenzerTProcalcitonin levels predict bacteremia in patients with community-acquired pneumonia: a prospective cohort trialChest2010138112112920299634
- BergPLindhardtBØThe role of procalcitonin in adult patients with community-acquired pneumonia – a systematic reviewDan Med J2012593A435722381083
- HuangDTWeissfeldLAKellumJARisk prediction with pro-calcitonin and clinical rules in community-acquired pneumoniaAnn Emerg Med20085214858.e218342993
- FlandersSASteinJShochatGPerformance of a bedside C-reactive protein test in the diagnosis of community-acquired pneumonia in adults with acute coughAm J Med2004116852953515063814
- KrügerSEwigSMarreRProcalcitonin predicts patients at low risk of death from community-acquired pneumonia across all CRB-65 classesEur Respir J200831234935517959641
- Baiat-MacoJNasirzadehEKharkiANaghiliBVarshojiMAssociation between serum procalcitonin level and CURB-65 criteria among patients with acute community acquired pneumoniaThe 21st Iranian Congress on Infectious Disease and Tropical MedicineJanuary 19–23, 2013Tehran
- LimWVan der EerdenMLaingRDefining community acquired pneumonia severity on presentation to hospital: an international derivation and validation studyThorax200358537738212728155
- UgajinMYamakiKHirasawaNYagiTPredictive values of semi-quantitative procalcitonin test and common biomarkers for the clinical outcomes of community-acquired pneumoniaRespir Care201459456447324170911
- KimJHSeoJWMokJHUsefulness of plasma procalcitonin to predict severity in elderly patients with community-acquired pneumoniaTuberc Respir Dis2013745207214
- LindstromSWongEProcalcitonin, a valuable biomarker assisting clinical decision-making in the management of community-acquired pneumoniaIntern Med J201444439039724528892
- WalshEFalseyANylenESerum biomarker measurements in adults with viral respiratory infections46th Annual Meeting of Infectious Diseases Society of America (IDSA)San FranciscoOctober 25–28, 2008
- PfisterRKochanekMLeygeberTProcalcitonin for diagnosis of bacterial pneumonia in critically ill patients during 2009 H1N1 influenza pandemic: a prospective cohort study, systematic review and individual patient data meta-analysisCrit Care2014182R4424612487
- SimonLGauvinFAmreDKSaint-LouisPLacroixJSerum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysisClin Infect Dis200439220621715307030
- BafadhelMClarkTWReidCProcalcitonin and C-reactive protein in hospitalizied adult patients with community-acquired pneumonia or exacerbation of asthma or COPDChest201113961410141821030489
- SchuetzPSuter-WidmerIChaudriAChrist-CrainMZimmerliWMuellerBPrognostic value of procalcitonin in community-acquired pneumoniaEur Respir J201137238439220595156